21:54:42 EDT Tue 01 Jul 2025
Enter Symbol
or Name
USA
CA



V:NRX - NurExone Biologic Inc. - https://www.nurexone.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NRX - V6.50.68·0.7536.00.70    0.83  0.52Jun 30Jun 2015 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-06-20 10:16C:NRX0.67News ReleaseNurexone Biologic joins HealthTech Hub program
2025-06-04 19:38C:NRX0.71News ReleaseNurexone presents at conference, to hold AGM June 18
2025-05-30 18:01C:NRX0.68News ReleaseNurexone Biologic adviser to present at ASIA meeting
2025-05-27 08:59C:NRX0.66News ReleaseNurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-27 08:42C:NRX0.66SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-05-27 08:42C:NRX0.66SEDAR Interim MD & ASEDAR Interim MD & A
2025-05-09 03:27C:NRX0.66News ReleaseNurexone's ExoPTEN data presented at annual meeting
2025-05-02 16:05C:NRX0.705News ReleaseNurExone Expands European Engagement with Investor Events in Germany and Switzerland
2025-04-24 16:55C:NRX0.64Private PlacementNurexone Biologic 3,543,238-share private placement
2025-04-24 16:15C:NRX0.64News ReleaseNurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
2025-04-22 20:18C:NRX0.65News ReleaseNurexone appoints Licht as CEO of Exo-Top
2025-04-09 17:16C:NRX0.68SEDAR MD & ASEDAR MD & A
2025-04-09 17:15C:NRX0.68News ReleaseNurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
2025-04-09 17:04C:NRX0.68SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-04-04 16:12C:NRX0.67News ReleaseNurexone closes $2.3-million private placement
2025-03-14 16:42C:NRX0.65News ReleaseNurexone completes preclinical study for ExoPTEN
2025-02-27 16:03C:NRX0.57News ReleaseNurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
2025-02-14 16:03C:NRX0.61News ReleaseNurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
2025-02-05 18:29C:NRX0.58News ReleaseNurexone Biologic forms U.S.-based subsidiary
2025-02-03 17:16C:NRX0.58Private PlacementNurexone Biologic 856,996-share private placement